» Articles » PMID: 21982629

Endoplasmic Reticulum Stress Induces Autophagy Through Activation of P38 MAPK in Fibroblasts from Pompe Disease Patients Carrying C.546G>T Mutation

Overview
Journal Mol Genet Metab
Specialty Endocrinology
Date 2011 Oct 11
PMID 21982629
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Pompe disease (glycogen storage disease type II) is an autosomal recessive myopathic disorder arising from the deficiency of lysosomal acid α-glucosidase (GAA). Activation of autophagy is a key pathophysiological feature in skeletal muscle fibers and fibroblasts from patients with Pompe disease. The accumulation of autophagic vacuoles has been shown to interfere with the efficacy of enzyme replacement therapy with recombinant human GAA. However, the induction mechanism of autophagy in Pompe disease is still unclear. In this study, we show that misfolded GAA-induced endoplasmic reticulum (ER) stress triggers autophagy in a manner regulated by p38 MAPK signaling pathways in fibroblasts from late-onset patients with Pompe disease. By studying normal fibroblasts and patient fibroblasts carrying a c.546G>T mutation, we uncovered that mutant GAA was rapidly degraded by proteasome. In addition, we found both activation of ER stress response and autophagy in these patient fibroblasts. Treatment with N-butyl-deoxynojirimycin (NB-DNJ), which acts as a pharmacological chaperone for certain mutant forms of GAA, led to attenuation of not only ER stress, but also autophagy in patient fibroblasts. Levels of phosphorylated p38 MAPK observed in patient fibroblasts were decreased after treatment with NB-DNJ. The autophagic response in patient fibroblasts was also negatively regulated by treatment with the p38 MAPK inhibitor SB203580. These findings define a critical role for ER stress in the activation of autophagy due to GAA mutation, and provide evidence that chaperone therapy may be a useful treatment for alleviation of autophagy in Pompe disease patients carrying a chaperon-responsive mutation.

Citing Articles

From Acid Alpha-Glucosidase Deficiency to Autophagy: Understanding the Bases of POMPE Disease.

Sanchez-Porras V, Guevara-Morales J, Echeverri-Pena O Int J Mol Sci. 2023; 24(15).

PMID: 37569856 PMC: 10419125. DOI: 10.3390/ijms241512481.


Dysregulation of Metabolism and Proteostasis in Skeletal Muscle of a Presymptomatic Pompe Mouse Model.

Rohm M, Volke L, Schlaffke L, Rehmann R, Sudkamp N, Roos A Cells. 2023; 12(12).

PMID: 37371072 PMC: 10297364. DOI: 10.3390/cells12121602.


Correlation of GAA Genotype and Acid-α-Glucosidase Enzyme Activity in Hungarian Patients with Pompe Disease.

Gal A, Grosz Z, Borsos B, Szatmari I, Sebok A, Javor L Life (Basel). 2021; 11(6).

PMID: 34072668 PMC: 8228169. DOI: 10.3390/life11060507.


Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease.

Wang J, Zhou C, Khodabukus A, Tran S, Han S, Carlson A Commun Biol. 2021; 4(1):524.

PMID: 33953320 PMC: 8100136. DOI: 10.1038/s42003-021-02059-4.


Cellular Stress in the Pathogenesis of Muscular Disorders-From Cause to Consequence.

Mensch A, Zierz S Int J Mol Sci. 2020; 21(16).

PMID: 32823799 PMC: 7461575. DOI: 10.3390/ijms21165830.